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Diabetes mellitus and impaired glucose tolerance 
are underdiagnosed in intensive care units 
Diabetes mellitus e intolerância à glicose são subdiagnosticados 
nas unidades de terapia intensiva
ORIGINAL ARTICLE
INTRODUCTION
Intensive care unit (ICU) inpatients frequently present disorders of glucose 
metabolism and sometimes require the administration of insulin. These disorders 
have been ascribed to endocrine-metabolic stress related to acute disease and to 
the effects of the multiple medications that are used to treat the patients.(1-3) 
Several mechanisms are responsible for hyperglycemia, such as activation of 
the hypothalamic-pituitary-adrenal axis, the secretion of corticosteroids and the 
release of catecholamines.(4-6)
The importance of undiagnosed diabetes mellitus (DM) or impaired glucose 
tolerance in the pathogenesis of hyperglycemia in critical patients is still not 
well-established.(7) Of the American population, 12.9% is diabetic, 40% of 
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ABSTRACT
Objective: To evaluate the presence 
of diabetes mellitus and impaired 
glucose tolerance in intensive care unit 
inpatients. 
Methods: The study included 
patients in post-surgical care for elective 
and emergency surgery and excluded 
those patients with known diabetes 
mellitus. To diagnose prior serum 
glucose level disorders, we considered the 
value of glycated hemoglobin (HbA1c) 
at the time of admission, classifying the 
patients as normal (<5.7%), glucose 
intolerant (5.7-6.4%) or diabetic 
(>6.4%). During the first 3 days of the 
patient’s hospital stay, glycemic control 
and clinical complications were assessed. 
Mortality was monitored for 28 days. 
For the statistical analyses, chi-square, 
ANOVA, student’s t, Kruskal-Wallis or 
Mann Whitney tests were used.
Results: Thirty patients were included 
in the present study, 53% of whom were 
women; the patients had a mean age of 
53.4±19.7 years and an APACHE II score 
of 13.6±6.6. The majority of patients 
were admitted for severe sepsis or septic 
shock followed by post-operative care 
for elective surgery, oncological surgery, 
multiple traumas and emergency surgery. 
When classifying these patients according 
to HbA1c, despite the absence of a prior 
history of diabetes mellitus, only 13.3% had 
a normal HbA1c level, 23.3% had levels 
compatible with the diagnosis of diabetes 
mellitus and 63.3% had levels compatible 
with impaired glucose tolerance. We 
found a significant association between the 
diagnosis of diabetes mellitus or impaired 
glucose tolerance and the use of vasoactive 
drugs (p=0.04).
Conclusion: A high prevalence of 
undiagnosed diabetes mellitus and impaired 
glucose tolerance was observed in inpatients 
at a general intensive care unit.
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whom are undiagnosed. A larger number of patients 
(29.5%) have underdiagnosed impaired glucose tolerance.
(8) Among inpatients, 12.4 to 25% are diabetic, many of 
whom do not have a prior diagnosis because the glycemia 
levels obtained during a hospital stay are not used to 
confirm the presence of DM.(9)
According to the American Diabetes Association 
(ADA),(10) the levels of glycated hemoglobin (HbA1c) 
began being utilized as a criterion for the diagnosis of DM 
and impaired glucose tolerance in January 2010. 
The goal of this study was to identify the presence of 
DM or impaired glucose tolerance among inpatients in 
a general ICU without a prior history of DM based on 
the HbA1c levels and the classification of DM according 
to the new guidelines established by the ADA in January 
2010.(10) Moreover, this study tested for the presence 
of correlations between high levels of HbA1c and the 
following events: hyperglycemic episodes, need for 
insulin administration, severe hypoglycemia, variability of 
glycemia and the incidence of clinical complications.
 
METHODS
Subjects
In this study, we prospectively included ICU inpatients 
older than 18 years who expected to stay at the ICU for 
at least 48 hours. All inpatients with a prior diagnosis 
of DM or impaired glucose tolerance, pregnant women 
and patients who were taking corticosteroids prior to 
admission to the ICU were excluded. The study was based 
on a convenience sample, and the inclusion of subjects was 
not consecutive. This ICU is within a public university 
hospital, and it admits highly complex patients sent by the 
Unified Health System (Sistema Único de Saúde - SUS).
The research protocol was approved by the Ethics 
Committee of the Universidade Federal de São Paulo 
(reference 0347/11; approved on April 15, 2011). All of 
the patients or their family members signed the informed 
consent form.
Protocol
At the time of admission to the ICU, a blood sample 
was collected to measure the HbA1c level. Demographic 
data were registered, and the Acute Physiological Chronic 
Health Evaluation II (APACHE II) score was calculated 
during the first 24 hours. Patients were monitored until 
their 3rd day at the ICU. Data for the fasting serum 
glucose (collected daily at 6 am as a routine procedure 
in this ICU) and capillary blood glycemic measurements 
were recorded, including the minimum, maximum and 
median values for each day. Glycemic monitoring was 
conducted without interference from the study protocol 
according to the clinical protocol in the unit. Any 
clinical complications within the first 3 days of inpatient 
care were also registered. After that period, the electronic 
medical record was used to access 28-day mortality. 
Hypoglycemia was defined as glycemia <75 mg/dL, 
and hyperglycemia was defined as levels >150 mg/dL 
according to the protocol already established by the unit. 
The use of insulin, both subcutaneous and intravenous, 
and the total dose were recorded.
The HbA1c levels were measured at the hospital clinical 
laboratory using a Tosoh A1c 2.2 high performance liquid 
chromatograph (Tosoh, Tokyo, Japan), certified by the 
National Glycohemoglobin Standardization Program. 
Complications, which were evaluated during the first 3 
days of inpatient care, included the development of sepsis/
severe sepsis/septic shock, the need for packed red blood 
cell transfusion, critical illness polyneuropathy, acute 
coronary syndrome, the need for dialysis and surgical 
complications. As the follow-up lasted for 3 days, the 
use of mechanical ventilation and the administration of 
vasoactive drugs, specifically, norepinephrine, epinephrine, 
dopamine and dobutamine, were evaluated at any time 
during this period. 
In agreement with the ADA publication,(8) patients 
were classified according to their HbA1c levels as normal 
(HbA1c<5.7%, Group 1), diabetic (HbA1c>6.4%, Group 
2) or glucose intolerant (HbA1c between 5.7% and 6.4%, 
Group 3).
Statistical analysis 
All quantitative variables were checked for normality 
using the Kolmogorov-Smirnov test. Normally distributed 
variables are expressed as the mean ± standard deviation, 
and values with a non-parametric distribution are 
expressed as the median (25-75%).
Categorical variables were analyzed using the chi-square 
test or Fisher’s exact test when appropriate. Quantitative 
variables were analyzed either with ANOVA and Student’s 
t-test (normal distribution) or with Kruskall-Wallis and 
Mann-Whitney tests (nonparametric variables). The 
Müller Dunn post-test was performed for the Kruskal-
Wallis test. To categorize continuous variables, the best 
cutoff point defined by the receiver operating characteristic 
curve was used. 
For statistical analyses, we used the Statistical Package 
for the Social Sciences (SPSS), version 19.0 (SPSS Inc., 
Chicago, IL, USA), and SigmaStat. The results were 
considered to be significant when p<0.05.
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RESULTS
 
In the sample of 30 patients included in the present 
study, 53% were female; the mean age was 53.4±19.7 years 
old, and the mean APACHE II was 13.6±6.6. The majority 
of the patients were admitted for severe sepsis or septic 
shock followed by post-operative care for elective surgery, 
oncological surgery, multiple trauma and emergency surgery 
(Table 1). The maximal length of hospital stay before the 
HbA1c measurement was collected was 15 days, and the 
lowest level of hemoglobin at collection was 7.2 mg/dL.
When classifying these patients according to their HbA1c 
levels, only 13.4% had normal HbA1c, 23.3% had undiagnosed 
diabetes and 63.3% had impaired glucose tolerance. These last 
two groups tended to have higher levels of blood glucose and a 
non-significant trend for greater variability (Table 2).
Among the complications studied, a statistically 
significant association was found between the change in 
the HbA1c level and the use of vasoactive drugs (p=0.04) 
(Table 3). Moreover, there was a higher frequency of 
vasoactive drugs administration among patients who were 
intolerant to glucose in comparison with diabetic patients.
Table 3 - Association between glycated hemoglobin and clinical variables
HbA1c<5.7% HbA1c
5.7-6.4%
HbA1>6.4% p 
value
Age 34.7±14.9 55.7±20.4 58.6±15.4 0.11
APACHE II 15.5±7.9 13.5±6.6 12.6±6.8 0.81
Men 2 (14.3) 10 (71.4) 2 (14.3) 0.55
RBC transfusion 1 (20) 2 (60) 1 (20) 0.82
Complications* 2 (20) 6 (60) 2 (20) 0.60
Use of vasoactive drugs 3 (18.7) 12 (75) 1 (6.3) 0.04
Days of mechanical 
ventilation
5 (4-5) 3 (0-5) 0 (0-2) 0.08
Insulin administration, day 1 0 (0) 5 (71.4) 2 (28.6) 0.46
Insulin administration, day 2 0 (0) 3 (60) 2 (40) 0.39
Insulin administration, day 3 0 (0) 3 (60) 2 (40) 0.26
28-day mortality 2 (33.3) 3 (50) 1 (16.7) 0.27
APACHE - Acute Physiological Chronic Health Evaluation; HbA1c - glycated hemoglobin. 
*Complications: sepsis/severe sepsis / sepsis chock development, need for packed red 
blood cells transfusion, polyneuropathy of critical patients, acute coronary syndrome, need 
for dialysis and surgical complications. Results are expressed as the number (%), the mean 
± standard deviation or the median (25-75%). Dunn test: p<0.05 for comparison between 
the HbA1c=5.7-6.4% group and the HbA1c<5.7% group. 
Table 2 - Association between glycated hemoglobin and glucose control
HbA1c<5.7% HbA1c
5.7-6.4%
HbA1c>6.4% p value
Serum glycemia D1 114±28 143±53 165±36 0.25
Maximum glycemia D1 145±11 178±78 216±60 0.47
Minimum glycemia D1 101±10 105±28 124±19 0.33
Median glycemia D1 124±12 130±33 157±28 0.21
Glycemia variation D1 44±15 76±78 89±77 0.71
Serum glycemia D2 112±7 144±75 164±36 0.22
Maximum glycemia D2 143±11 204±97 199±45 0.73
Minimum glycemia D2 99±22 95± 25 106±15 0.68
Median glycemia D2 108±19 126±28 143±31 0.22
Glycemia variation D2 44±12 113±10 97±53 0.67
Serum glycemia D3 100±15 109±35 160±67 0.31
Maximum glycemia D3 133±10 158±62 250±137 0.27
Minimum glycemia D3 87±2 98±25 105±24 0.52
Median glycemia D3 112±16 124±26 158±46 0.23
Glycemia variation D3 46±10 60±57 145±156 0.75
HbA1c - glycate hemoglobin. Results expressed in mean ± standard deviation.
Table 1 - Sample characterization
Variable Result
Gender, women 16 (53)
Age (years) 53.4±19.7
APACHE II 13.6±6.6
HbA1c (%) 5.9 (5.7-6.2)
Reason for ICU hospitalization
Severe sepsis/sepsis shock 9 (30)
Post-op care for elective surgery 6 (20)
Post-op care for oncologic surgery 5 (16.7)
Multiple trauma 4 (13.3)
Post-op care for emergency surgery 2 (6.7)
Stroke 2 (6.7)
Post-op care for liver transplantation 1 (3.3)
Other clinical complications 1 (3.3-2.5)
APACHE - Acute Physiological Chronic Health Evaluation; HbA1c - glycated hemoglobin; 
ICU - intensive care unit. Results are expressed the number (%), the mean ± standard 
deviation or the median (25-75%).
DISCUSSION
In this study, the prevalence of DM and impaired 
glucose tolerance was assessed in a population of ICU 
inpatients. For this assessment, HbA1c was used to 
diagnose these conditions according to ADA standards. 
Our findings suggest a high prevalence of undiagnosed 
diabetes, especially impaired glucose tolerance, prior to 
hospital admission.
The measurement of HbA1c is widely used for 
the outpatient control of diabetic patients.(11,12) In the 
literature, this level may also correlate stress hyperglycemia 
with the presence of undiagnosed DM.(13-18) Silverman et 
al. analyzed patients who were admitted to the emergency 
department with acute diseases and had an episode 
of hyperglycemia; those patients with HbA1c≥6.2% 
were characterized as having undiagnosed diabetes.(13) 
When analyzing trauma patients, Kopelman et al. 
considered values of HbA1c≥6% as indicating a “hidden” 
DM diagnosis.(14) Husband et al. found that levels of 
HbA1c>7.5% indicated prior DM in patients with acute 
myocardial infarction (AMI).(15)
These different studies indicate that there has 
been no standardized HbA1c level for the diagnosis 
of DM. The ADA selected the value of 5.7% for 
HbA1c as a cutoff value for having an increased risk of 
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developing DM because this value reflects an average 
fasting blood glucose of 100 mg/dL over the past 2 to 
3 months.(10) A large prospective study showed that 
a HbA1c threshold of 5.7% has a sensitivity of 66% 
and specificity of 88% for identifying the incidence of 
DM in 6 years of follow-up.(19) In addition, patients 
with an HbA1c level slightly below the previous 
mentioned cutoff value, ranging from 6 to 6.5%, have 
a high risk of developing DM, ten times higher than 
those patients with lower levels.(20)
Interestingly, hospitalized patients with hyperglycemia 
but without a history of DM have a higher risk of adverse 
events, including increased hospital mortality, than patients 
with diabetes.(21) In these patients, the diagnosis and 
treatment of hyperglycemia may have underappreciated.
The association between impaired glucose tolerance 
and the greater need for vasoactive drugs does not 
necessarily imply causation, and intolerance may simply 
represent a marker of severity. However, this association 
may represent greater hemodynamic instability in these 
patients due to increased susceptibility resulting from 
previously developed microcirculation changes. In an 
assessment of glycemic control in the intensive care 
setting, an association between glycemia and vasoactive 
drugs was identified. In that group of patients, the odds 
ratio of developing a glycemia level <40 mg/dL was 0.61 
(0.52 to 0.71) (p<0.001).(22) Another important factor is 
that capillary blood glucose levels may be overestimated in 
patients using vasoactive drugs. When comparing venous 
and capillary blood glycemia, Critchell at al. found that in 
83% of patients, capillary blood glucose was higher than 
venous blood glucose, and 25% of these patients used 
norepinephrine.(23) However, in the present study, glucose 
was measured in blood collected from the arterial catheter, 
which was used to monitor blood pressure, for patients 
receiving vasoactive drugs; therefore, this study has no 
such bias.
This study has several limitations. The main one is 
the small number of patients, which can hinder some 
conclusions, especially regarding the analysis of associated 
factors. The small number of patients did not allow for a 
multivariate analysis. Moreover, this study includes only 
one center, and the patients were monitored for glycemic 
control and complications only during the first 3 days of 
ICU inpatient care. Nonetheless, this novel assessment 
protocol for critically ill patients uses the HbA1c level to 
allow for the early diagnosis of DM and impaired glucose 
tolerance, which have been previously underdiagnosed in 
this population.
CONCLUSIONS
In this sample of patients who were admitted to a 
general ICU, we found a high frequency of diabetes or 
impaired glucose tolerance without prior diagnosis.
RESUMO
Objetivo: Avaliar a presença de diabetes mellitus e a intole-
rância à glicose em pacientes internados em unidades de terapia 
intensiva.
Métodos: Foram incluídos pacientes clínicos, em pós-ope-
ratório de cirurgias eletivas e de urgência, e excluídos aqueles 
com história de diabetes mellitus. Para o diagnóstico de altera-
ções prévias da glicemia, utilizou-se a dosagem da hemoglobina 
glicada (HbA1c) na admissão do paciente, sendo classificado em 
normal (<5,7%), intolerante à glicose (5,7-6,4%) ou diabéti-
co (>6,4%). Durante os 3 primeiros dias da internação, foram 
avaliados o controle glicêmico e as complicações clínicas. A evo-
lução para óbito foi acompanhada por 28 dias. Para as análises 
estatísticas, utilizaram-se testes do qui-quadrado, ANOVA, teste 
t de Student, Kruskall-Wallis ou Mann Whitney.
Resultados: Foram incluídos 30 pacientes, 53% do gênero 
feminino, idade de 53,4±19,7 anos e APACHE II de 13,6±6,6. 
A maioria dos pacientes foi admitida por sepse grave ou choque 
séptico, seguido por pós-operatório de cirurgias eletivas, onco-
lógicas, politraumatismo e cirurgia de urgência. Ao classificar 
esses pacientes segundo a HbA1c, apesar da ausência prévia de 
história de diabetes mellitus, apenas 13,3% tinham HbA1c nor-
mal, 23,3% tinham níveis compatíveis com o diagnóstico de 
diabetes mellitus e 63,3% eram compatíveis com intolerância 
à glicose. Houve associação significativa entre o diagnóstico de 
diabetes mellitus ou intolerância a glicose e o uso de droga va-
soativa (p=0,04).
Conclusão: Foi encontrada alta prevalência de diabetes 
mellitus e intolerância à glicose, sem diagnóstico prévio, em pa-
cientes internados em uma unidade de terapia intensiva geral.
Descritores: Transtornos do metabolismo da glucose; 
Diabetes mellitus; Hiperglicemia; Terapia intensiva; 
Hemoglobina A glicosilada; Catecolaminas
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